Furthermore, clinical trials have established that GLP-1 receptor agonists, including liraglutide, dulaglutide, and semaglutide, are effective in reducing major adverse cardiovascular events (MACE) in people with type 2 diabetes [3,4,5]. Here, GLP1R is linked to type 2 diabetes mellitus.